• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

    7/29/25 11:21:47 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Cytek Biosciences Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    23285D109

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23285D109


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    75,816.00
    7Sole Dispositive Power

    7,576,120.00
    8Shared Dispositive Power

    189,018.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,765,138.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.13 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cytek Biosciences Inc
    (b)Address of issuer's principal executive offices:

    46107 Landing Parkway, Fremont, CA, 94538
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    23285D109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    7765138
    (b)Percent of class:

    6.13  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    75816

     (iii) Sole power to dispose or to direct the disposition of:

    7576120

     (iv) Shared power to dispose or to direct the disposition of:

    189018

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $CTKB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    8/17/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 21,031 shares and covered exercise/tax liability with 5,738 shares, increasing direct ownership by 0.25% to 6,057,419 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    8/20/25 5:58:33 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 7,371 shares and covered exercise/tax liability with 2,872 shares, increasing direct ownership by 24% to 23,416 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    8/20/25 5:56:53 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF LEGAL OFFICER Barnett Valerie covered exercise/tax liability with 8,829 shares and converted options into 24,307 shares, increasing direct ownership by 18% to 99,151 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    8/20/25 5:49:35 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cytek Biosciences downgraded by TD Cowen with a new price target

    TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

    5/9/25 8:41:00 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by Goldman with a new price target

    Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

    1/31/25 6:59:30 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Stephens initiated coverage on Cytek Biosciences with a new price target

    Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

    12/14/23 6:55:41 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytek Biosciences to Participate in Upcoming Investor Conferences

    FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Precision Medicine Summit in Dana Point, CAPanel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time Wells Fargo Healthcare Conference in Boston, MAParticipating in investor 1x1 meetings on Thursday, September 4, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYFireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time

    8/12/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports Second Quarter 2025 Financial Results

    FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, and representing 3% unit growth of Cytek FSP® instruments compared to the second quarter of 2024Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on

    8/6/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025

    FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

    7/23/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    6/3/25 5:39:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    SEC Filings

    View All

    SEC Form 10-Q filed by Cytek Biosciences Inc.

    10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)

    8/6/25 5:17:35 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

    8/6/25 4:11:56 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

    SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    7/29/25 11:21:47 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    View All

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Cytek Announces Resignation of Chief Operating Officer Chris Williams

    FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

    9/12/24 3:20:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek® Biosciences Names William McCombe Chief Financial Officer

    Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

    3/19/24 8:00:00 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Financials

    Live finance-specific insights

    View All

    Cytek Biosciences Reports Second Quarter 2025 Financial Results

    FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, and representing 3% unit growth of Cytek FSP® instruments compared to the second quarter of 2024Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on

    8/6/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025

    FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

    7/23/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports First Quarter 2025 Financial Results

    FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

    5/8/25 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials